Open AccessFDA's Breakthrough Designation to Blinatumomab and CTL019 for ALL
Publication year - 2014
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000453430.23841.38
Subject(s) - blinatumomab , business , actuarial science , medicine , lymphoblastic leukemia , leukemia